Board Meeting on August 12, 2016
Kilitch Drugs India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on August 12, 2016, inter alia, to consider the following;1. To take on record the Unaudited (Provisional] Financial Results for the Quarter ended June 30, 2016 along with the Limited Review Report;2. To adopt and approve the Notice & Directors Report of the Company along with the Corporate Governance Report for financial year 2015-2016;... Standalone & Consolidated Financial Results, Auditors Report for March 31, 2016
Kilitch Drugs India Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Auditors Report for the period ended March 31, 20164. Consolidated Auditors Report for the period ended March 31, 20165. Declaration regarding Audit Report with unmodified opinion Board Meeting Intimation for Results & Closure of Trading Window
Kilitch Drugs India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on May 30, 2016, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2016.Further, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in... Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Paresh P Mehta has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 Change in composition of the Board of Directors
Kilitch Drugs India Ltd has informed BSE that Mr. Paresh Mehta has tendered his resignation as the Jt. Managing Director of the Company and consequently he ceased to be the Director of the Company w.e.f. April 13, 2016. Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Mukund P Mehta has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Mukund P Mehta has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
Mukund Mehta has submitted the disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011 Outcome of Board Meeting
Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 11, 2016, have:- Decided and approved to enter into an agreement with respect to capital contribution with Arham Neeta Realities LLP and authorized any of the Director(s) of the Company in this regard, on behalf of the Company.